

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : B65D 75/34, 75/58		A1	(11) International Publication Number: WO 00/24647
			(43) International Publication Date: 4 May 2000 (04.05.00)
(21) International Application Number: PCT/EP99/07974			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 20 October 1999 (20.10.99)			
(30) Priority Data: 09/177,477 22 October 1998 (22.10.98) US			
(71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).			
(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).			
(72) Inventor; and (75) Inventor/Applicant (for US only): DANVILLE, David, Roy [US/US]; 39 Church Street, Millburn, NJ 07041 (US).			
(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).			

Published
With international search report.

(54) Title: CHILD RESISTANT PACKAGE AND METHOD OF DISPENSING MEDICATION



(57) Abstract

A child-resistant, adult friendly package is disclosed. The package is designed to require a sequence of opening steps too complex for a child to perform, but simple enough for an adult to perform. The package is formed from a top having a surface that projects from one face of the top sheet and forms a recess in the opposite face of the top sheet, a bottom sheet overlying the opposite face of the top sheet, arranged to enclose the recess, a sealed portion (30) and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion, and a tear slit (40) located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CHILD RESISTANT PACKAGE AND
METHOD OF DISPENSING MEDICATION

Field of the Invention

The subject invention relates to a package used to hold medication in a child resistant manner. More specifically, the invention relates to a blister package that, while remaining child resistant, may be easily opened by adults and senior citizens. The invention also relates to a method for dispensing medication from the package.

Background of the Invention

The packaging industry offers a wide array of packages or dispensers to safely contain potentially hazardous materials. For example, manufacturers have typically designed such packages to hold medication dosages in a child resistant manner. By their child resistant design, the packages lessen the chances that a child will gain access to the medication and therefore prevent the occurrence of an overdose.

A problem has occurred with child resistant packages, however, in that the packages have sometimes prevented the intended recipient of the medication from accessing the medication. Depending on the difficulty of the step or steps needed to open the package, certain adults may find it inconvenient or even nearly impossible to access the medication. The difficulty in opening the packages can be further aggravated for senior citizens and persons having infirmities or physical weaknesses that affect their motor skills. At best, conventional child resistant packages may present an inconvenience. At worst, conventional child resistant packages may discourage and/or prevent the intended recipient of the medication from taking the prescribed dosages. Clearly, a need exists for improved packages that are child resistant but remain reasonably accessible for adults to open.

United States Patent No. 5,046,618 relates to a child resistant blister package that is opened by a sequence of actions. First, a tear is made in a first direction running in between the blister packs. A second tear is made perpendicular to the first tear, also in a direction running in between the blister packs. The second tear intersects the first

tear and isolates a single blister pack. A third tear is made, again in a direction that does not lead directly to the blister pack. The third tear exposes an unsealed area at a corner of the isolated blister pack, thereby allowing a bottom packaging layer to be peeled from an upper layer to expose the medication in the blister pack.

5 United States Patent No. 5,088,603 also relates to a child resistant package. In the '603 patent, individual blister packs are separated from one another by perforation lines. For each blister pack, a tear slit is located to bisect the longitudinal axis of each blister and to extend less than one third of the distance between a perforation edge and the blister. Thus, the tear slit allows the user to tear the package in the direction of the
10 blister.

Summary of the Invention

An object of the present invention is to provide a package that is child resistant.

Another object of the present invention is to provide a package that is
15 accessible to senior citizens.

Another object of the present invention is to provide a package that requires more than one step to access medication contained therein.

To achieve these and other objects and in accordance with the purpose of the present invention, as embodied and broadly described herein, the present invention
20 relates to a package formed by a top sheet having a surface that projects from one face of the top sheet and forms a recess in the opposite face of the top sheet; a bottom sheet overlying said opposite face of the top sheet, arranged to enclose the recess; a sealed portion and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion; and a
25 tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package.

The present invention also relates to a method of dispensing medication contained in a recess of the package, wherein the method includes folding the package to form a folded edge exposing the tear slit at the folded edge; initiating a tear at the
30 exposed tear slit and continuing the tear to intersect the unsealed area; peeling either

the top sheet or the bottom sheet to expose the medication contained in the recess of the separated unit; and dispensing the medication from the package.

The present invention also relates to a method of dispensing medication contained in a recess of a package, wherein the package has a top sheet having a surface that projects from one face of the top sheet and forms a recess in the opposite
5 face of the top sheet, a bottom sheet overlying said opposite face of the top sheet, arranged to enclose the recess, and a tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package; and the method includes folding the package to form a folded edge exposing the tear
10 slit at the folded edge, initiating a tear at the exposed tear slit and continuing the tear to intersect the recess and provide access to the medication, and dispensing the medication from the package.

Brief Description of Drawings

15 Figure 1 shows a package having a plurality of blisters arranged in rows.

Figure 2 shows a blister unit being separated by tearing along a first line of weakness.

Figure 3 shows the step of folding along a third line of weakness to expose a notch.

20 Figure 4 shows the step of initiating a tear and propagating the tear in a direction substantially parallel to the blister towards an unsealed area of the package.

Figure 5 shows the step of separating the bottom sheet away from the blister sheet at the unsealed area of the package.

25 Figure 6 shows the step of peeling the bottom sheet away from the top sheet to expose the contents of the package.

Detailed Description of the Preferred Embodiments

The package described herein advantageously requires, in order to open that package, several sequential steps. In one embodiment, the package comprises a top sheet having a surface that projects from one face of the top sheet and forms a recess

in the opposite face of the top sheet, a bottom sheet overlying said opposite face of the top sheet and enclosing the recess, a sealed portion and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion.

5 As used herein, the term "recess" embraces the area of the package intended to hold the medication.

 The bottom sheet of the package may typically be flat, or it may also have a surface projecting from one face to form a recess in the opposite face of the bottom sheet. Such a recess in the bottom sheet, also known as the lidding sheet, would
10 typically be aligned with the recess in the top sheet to provide additional space for the medication to be held.

 The package also includes a tear slit extending between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package. Preferably, the tear slit extends in a direction away from the recess and
15 towards the unsealed portion. In a preferred embodiment, the package comprises a plurality of recesses or blisters substantially arranged in rows, with a first line of weakness and a second line of weakness in the top sheet and/or bottom sheet, wherein said first and second lines extend substantially between opposite edges of the package and substantially between the rows of blisters. In that preferred embodiment, the tear
20 slit does not contact any edge of the package and does not contact either the first or second line of weakness.

 Referring now to the figures, which depict preferred embodiments of the claimed invention, Figure 1 shows a blister package having four blisters 10 arranged substantially in rows. In between the rows, a first line of weakness 22 and a second
25 line of weakness 24 extend substantially between opposite edges of the blister package, separating the rows. Each blister of the blister package is also located in proximity to an unsealed area 30 and a preferred third line of weakness 26. The third line of weakness 26 may run in a direction substantially parallel to either the first or second line of weakness, or substantially parallel to an edge of the blister package. As
30 shown in Figure 1, in a preferred embodiment the third line of weakness is located between either the first or second lines of weakness and the unsealed area 30 and is spaced apart from each.

The package also contains a tear slit 40 that is spaced apart from and does not contact any edge of the package. Tear slit 40 is also spaced apart from and does not contact either the first line of weakness 22 or the second line of weakness 24.

Preferably, tear slit 40 is located so that the package cannot be opened by initiating a tear at an edge and through the slit, without applying a substantial tearing force.

Instead, the slit 40 is located so that the user must fold the package to create an edge at the fold line and expose the slit 40. Once slit 40 is exposed at an edge, the user may then initiate a tear at the slit in a direction towards the unsealed area 30.

The tear slit may have any shape and may be arranged in any direction, although a slit arranged so that it leads in the direction of unsealed area 30 is preferred. In a preferred embodiment, the tear slit forms an angle or is V-shaped. When the package is folded, the resulting fold line defines an edge that intersects the tear slit. Preferably, the fold line intersects the tear slit at the vertex of any angle formed by the tear slit.

Once the package is folded to form an edge exposing the tear slit, a tear is initiated through the tear slit. Generally, the direction and arrangement of the tear slit influences the direction of the tear. As shown in Figure 4, tear 50 is initiated through a folded or double layer of the blister package material. In other words, because the tear slit is exposed at an edge by first folding the top sheet 15 and the bottom sheet 25, tear 50 at tear slit 40 is actually initiated through two layers of the top sheet and two layers of the bottom sheet. In such an embodiment, the tear slit should be designed so that the intended user may tear the folded package material without too much difficulty.

To this end, the distance from the slit to the edge of the package should be reduced to reduce the distance that the tear 50 must propagate through folded package material.

At the same time, however, the distance from the slit to the edge of the package should not be so small that children may initiate a tear at an edge of the package without the folding step.

In a preferred embodiment, the tear slit crosses the third line of weakness 26. In that embodiment, the user folds the package along the third line of weakness 26 to form an edge exposing tear slit 40, as shown in Figure 3. Preferably, as also shown in Figure 3, the tear slit 40 intersects a perforation in third line of weakness 26. Thus,

tear slit 40 forms an angle bisected by the third line of weakness into two, not necessarily equal parts.

The term "tear slit" is used herein for convenience only. As used herein, the term "tear slit" means any weakness in the package material through which a tear may be initiated. Examples of such a weakness include, but are not limited to, partial or full perforations, scores, or cuts.

Unsealed area 30, formed between the top sheet 15 and the bottom sheet 25, is preferably located between tear slit 40 and blister 10. Preferably, a portion of either the top sheet or the bottom sheet is raised away from the other sheet to facilitate grasping the sheets after the tear is made through tear slit 40. A ridge may be placed in the raised area, e.g. between the blister and the tear slit, to guide the tear initiated at the tear slit away from the blister. Although unsealed area 30 may contact blister 10 or tear slit 40, a preferred blister package locates the unsealed area 30 away from both the blister 10 and tear slit 40 as shown in Figure 1. Thus, the distance between the slit and the unsealed area affects the amount of force needed to propagate tear 50 towards unsealed area 30. Similarly, the distance between unsealed area 30 and blister 10 affects the amount of force needed to peel the bottom sheet and top sheet from one another.

As used herein, the term "unsealed area" also embraces an area of the package where a portion of either the top sheet or the bottom sheet is omitted. Thus, once the user tears the package at the slit and to the area where one sheet is absent, the remaining sheet is exposed so that the user can grasp it and peel it away from the corresponding sheet to expose the medication in the blister.

In an optional embodiment, the package may also have a channel extending partially or entirely between tear slit 40 and unsealed area 30. The channel guides the tear initiated at tear slit 40 in the desired direction toward unsealed area 30. The channel may be, for example, a fourth line of weakness.

Although the figures show the first, second, and third lines of weakness as lines of perforations, other mechanisms substantially equivalent to perforations may be used. For example, prefolded lines or scores may be used, or the lines of weakness may be formed by cuts made through or partially through either the top sheet or the bottom sheet. Similarly, any combination of prefolded lines, perforations, scores, or cuts may

be used. For a line of weakness having perforations or scores, one may increase or decrease the ratio of cut area to the uncut area to adjust the force needed to tear or fold the package along that line of weakness. The location of the lines of weakness may be also varied to control the force and effort needed to open the package. For
5 example, one may move the first and second lines of weakness further away from the package's edge to increase the force needed to isolate a single blister unit by tearing along the first and second lines of weakness.

The actual dimensions of the package may be varied by one of ordinary skill in the art to suit the particular end use desired. For example, the shape and size of the
10 medication will determine the size of the blister. Thus, a typical blister may have a size of 28 mm x 18 mm. The distance between the blister and the first or second perforation lines may be 1 to 18 mm, preferably 12 mm; the distance between the blister and the unsealed area may range from 2 to 6 mm, preferably 4 mm; the distance
15 between the start of the first or second perforation lines and an edge may range from 2 to 8 mm, preferably 5 mm; the dimensions of the tear slit may range from 1 to 20 mm, preferably broken into two segments of 5 and 2 mm; the distance between the tear slit and the first or second perforation lines may range from 1 to 3 mm, preferably 2 mm, the distance between the tear slit and the unsealed area may range from 0 to 5 mm, preferably 0 mm, and the distance between the third line of weakness and its parallel,
20 first or second line of weakness may range from 2 to 6 mm, preferably 4 mm.

Figures 2 through 6 depict a preferred method of dispensing medication from a package described herein. Figure 2 shows a blister package having four blisters arranged substantially in rows, with first line of weakness 22 and second line of
25 weakness 24 running between the rows and from one edge of the blister package to the opposite edge. The user first tears first line of weakness 22 and then tears second line of weakness 24 to separate a single blister unit from the blister package.

Figure 3 shows a separated blister unit. As shown in Figure 3, the user then folds the package along third line of weakness 26 to form a folded edge along the third
30 line of weakness. Tear slit 40 is then exposed at the folded edge. As shown in Figure 4, the user then initiates a tear 50 at exposed tear slit 40 in a direction running toward and continuing to unsealed area 30. As also shown in Figure 4, tear 50 is initiated at a point located away from and not contacting unsealed area 30. Because of the folded

edge along third line of weakness 26, tear 50 initially propagates through a double layer of packaging material, i.e. two layers of the top sheet 15 and two layers of the bottom sheet 25.

Once the user tears the package through the unsealed area 30, bottom sheet 25
5 and top sheet 15 are then exposed in an unsealed state where the user can grasp them. The user then peels the bottom sheet 25 and the top sheet 15 away from one another as shown in Figures 5 and 6. Preferably, the user will turn the blister package so that the medication remains in the recess formed by blister 10 before peeling the bottom sheet 25 and top sheet 15 from one another. The medication may then be administered
10 at the proper dosage for its intended use.

The package may optionally include a third, "push through" sheet sandwiched between the top sheet and the bottom sheet. In this embodiment, after the tear is initiated at tear slit 40 and is propagated to the unsealed area, the bottom sheet is peeled away from the top sheet and the third sheet so that, after peeling, the
15 medication remains inaccessible. The user must then push the medication through the third sheet after the lidding sheet is peeled away. In an alternative embodiment, the push through sheet is formed by a multilayer bottom sheet constructed so that, upon peeling, one or more of the layers remain behind. In such an embodiment, the medication may then be pushed through any layers of the bottom sheet that remain in
20 place after peeling. In any case, the construction of the third sheet and the bottom sheet should not allow the medication to be pushed through the two sheets and accessed. Thus, the third sheet builds an additional step into the opening sequence.

The package may be constructed out of any materials typically used to produce conventional blister packages. For example, the top sheet, the bottom sheet, and/or
25 the third, "push-through" sheet may be constructed of materials such as acrylonitrile (e.g. Klockner PENTAPHARM® PH 8B7/08), polyethylene terephthalate (e.g. Klockner PENTAPHARM® PH 8G1), polypropylene (e.g. Klockner PENTAPHARM® PH 885/76), polyvinyl chloride (e.g. VPI MIRREX®1025), plastic multilayer structures (e.g. Klockner PENTAPHARM® A 200/02 and TECHNI-PLEX VDC®
30 250-25-90), aluminum based multilayer structures such as polyamide/aluminum foil/polyvinyl chloride (e.g. Lawson MARDON® 15126), or paper based multilayer structures.

Preferably, the top sheet is a blister sheet constructed of Lawson MARDON® 90256 polyvinyl chloride/polyamide/aluminum foil/polyvinyl chloride and has a weight ranging from 320 g/m² to 400g/m², more preferably 360 g/m². The bottom sheet is preferably constructed of Reynolds SAFETY-PAK® 204 paper/polyester/aluminum foil/polyvinyl chloride having a weight of about 77 to about 95 pounds per ream, more preferably about 86 pounds per ream.

The sheets used to form the package may be sealed together by heat sealing or with adhesives, or any combination thereof. All seals should be secure to prevent access to the medication without performing the previously described steps.

Preferably, the top sheet and bottom sheet are heat sealed together by any means known and conventionally used in the art.

The package may be used to contain any kind of medication, e.g. formoterol.

Other embodiments of the present invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and figures be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

We claim:

1. A package comprising:
 - (a) a top sheet having a surface that projects from one face of the top sheet and forms a recess in the opposite face of the top sheet,
 - 5 (b) a bottom sheet overlying said opposite face of the top sheet, arranged to enclose the recess,
 - (c) a sealed portion and an unsealed portion formed between the top sheet and the bottom sheet, wherein each recess is associated with a sealed portion and an unsealed portion, and
 - 10 (d) a tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package.
2. The package of claim 1, wherein the tear slit is located a distance away from any edge of the package so that a tear may not be initiated at an edge of the
15 package and propagated through the tear slit.
3. The package of claim 1, wherein the tear slit forms an angle.
4. The package of claim 1 having a plurality of recesses arranged in rows,
20 further comprising a first line of weakness and a second line of weakness in the top sheet and/or bottom sheet, wherein said first and second lines extend substantially between opposite edges of the package substantially between the rows of recesses and the tear slit does not contact either the first or second lines of weakness.
- 25 5. The package of claim 4, wherein the tear slit does not contact the unsealed area.
6. The package of claim 4, wherein the tear slit extends to substantially contact the unsealed area.
30
7. The package of claim 4, wherein the tear slit is located a distance away from any edge of the package and the first and second lines of weakness so that a tear may not be initiated at an edge of the package and propagated through the tear slit.

8. The package of claim 4, wherein the tear slit forms an angle.

9. The package of claim 4, wherein the first and second lines of weakness
5 are perforated.

10. A method of dispensing medication contained in a recess of the package
of claim 4, wherein said method comprises:

tearing the first line of weakness and/or second line of weakness to separate a
10 unit containing a recess,

folding the separated unit to form a folded edge exposing the tear slit at the
folded edge,

initiating a tear at the exposed tear slit and continuing the tear to intersect the
unsealed area of the separated unit,

15 peeling either the top sheet or the bottom sheet at the unsealed area to expose
the medication contained in the recess of the separated unit,

dispensing the medication from the package.

11. A method of dispensing medication contained in the recess of the
20 package of claim 1, wherein said method comprises:

folding the package to form a folded edge exposing the tear slit at the folded
edge,

initiating a tear at the exposed tear slit and continuing the tear to intersect the
unsealed area,

25 peeling either the top sheet or the bottom sheet at the unsealed area to expose
the medication contained in the blister, and

dispensing the medication from the package.

12. A method of dispensing medication contained in a recess of a package,
30 wherein the package comprises

(a) a top sheet having a surface that projects from one face of the top sheet and
forms a recess in the opposite face of the top sheet,

(b) a bottom sheet overlying said opposite face of the top sheet, arranged to enclose the recess, and

(c) a tear slit located between the unsealed portion and an edge of the package, wherein the tear slit does not contact any edge of the package; said method

5 comprising:

folding the package to form a folded edge exposing the tear slit at the folded edge,

initiating a tear at the exposed tear slit and continuing the tear to intersect the recess and provide access to the medication, and

10 dispensing the medication from the package.

13. The method of claim 12, wherein the package has a plurality of recesses arranged in rows, with a first line of weakness and a second line of weakness in the top sheet and/or bottom sheet, wherein said first and second lines extend substantially
15 between opposite edges of the package substantially between the rows of recesses and the tear slit does not contact either the first or second lines of weakness; wherein the method comprises tearing the first line of weakness and/or second line of weakness to separate a unit containing a recess before folding the package to form a folded edge exposing the tear slit at the folded edge.

20

14. A package according to claim 1 comprising formoterol.

25

1/3




FIG. 1




FIG. 2

2/3




FIG. 3




FIG. 4




FIG. 5




FIG. 6

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.
PCT/EP 99/07974

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 B65D75/34 B65D75/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 B65D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 511 665 A (G.D. SEARLE & CO) 30 April 1996 (1996-04-30) column 4, line 47 -column 6, line 67; figures 1-8	1,2
Y	US 4 398 634 A (WRAPADE MACHINE) 16 August 1983 (1983-08-16) column 3, line 60 -column 4, line 62; figures 3,4	1-13
Y	US 3 835 995 A (PACO PACKAGING) 17 September 1974 (1974-09-17) column 2, line 20 -column 4, line 10; figures 1-5	1-13
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 February 2000

Date of mailing of the international search report

16/02/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Lenoir, C

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/EP 99/07974

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3 809 220 A (BECTON, DICKINSON AND CO) 7 May 1974 (1974-05-07) column 2, line 59 -column 5, line 23; figures 1-14 ----	1
A	US 5 325 968 A (MCNEIL-PPC) 5 July 1994 (1994-07-05) column 3, line 4-50; figures 1-4 ----	1
A	US 4 243 144 A (STERLING DRUG) 6 January 1981 (1981-01-06) column 2, line 40 -column 3, line 52; figures 1-5 -----	1

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/EP 99/07974

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5511665 A	30-04-1996	NONE	
US 4398634 A	16-08-1983	NONE	
US 3835995 A	17-09-1974	CA 988465 A GB 1381218 A JP 957042 C JP 49043793 A JP 53040156 B US 3924746 A	04-05-1976 22-01-1975 14-06-1979 24-04-1974 25-10-1978 09-12-1975
US 3809220 A	07-05-1974	CA 991571 A	22-06-1976
US 5325968 A	05-07-1994	CA 2127910 A EP 0634342 A GR 94100355 A	15-01-1995 18-01-1995 22-05-1996
US 4243144 A	06-01-1981	NONE	